{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '9.7.', '9.7.1.', '67', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '9.8. Protocol Amendments', 'Any changes to the study protocol will be made in the form of an amendment and must', 'be approved by the IRB before implementation. These changes may only be made by', 'the Sponsor-Investigator (Dr. Michael Schweizer). Changes to the protocol or informed', 'consent form will be reviewed and approved by Janssen Scientific Affairs, LLC prior to', 'submitting to the IRB for approval.', '9.9. Informed consent', 'Written informed consent will be obtained by a study investigator, or delegated Sub-', 'Investigator working on this study. An explanation of the nature of study, its purpose,', 'procedures involved, expected duration, potential known risks and benefits will be', 'provided to each participant by the investigator or the delegated Sub-Investigator. Each', 'participant will be informed that participation in the study is voluntary and that they may', 'withdraw from the study at any time, and that withdrawal of consent will not affect their', 'subsequent medical treatment. Participants will be allowed time needed to make an', 'informed decision. Participants will be encouraged to ask questions about the study and', 'the consent before signing the consent form. Original signed consent forms will be filed', \"in each patient's research chart, while each patient will receive a copy of the consent\", 'document. No patient will enter the study before the informed consent has been', 'obtained.', 'The Research Coordinator and the Regulatory Coordinator at the coordinating center', 'will be made aware of new participants via email. The Sponsor-Investigator will be', 'responsible for reviewing the informed consent forms from participating sites and', 'verifying eligibility. Once it has been confirmed that a new candidate has provided', 'consent and is eligible to participate in the study, the coordinating center will register the', \"patient and provided him with a unique study identification number. New participants'\", 'study checklist and informed consent form should be emailed to:', 'Zoya Bauer: zbauer@seattlecca.org', 'and', 'CC9582@seattlecca.org', '68', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '10. Statistical Methods', 'This is an open label, multi-site study to evaluate apalutamide in men with very low-risk', \"to low-intermediate risk prostate cancer (see 'risk' definitions under Inclusion Criteria)\", 'enrolled on active surveillance. The primary endpoint for this trial will be the absence of', 'residual carcinoma (i.e., a negative repeat biopsy) as determined by targeted and', 'systematic biopsies following 90-days of apalutamide. The primary objective will be to', 'determine the negative repeat biopsy rate following 90-days of apalutamide for all men', 'enrolled. The negative repeat biopsy rate will be continuously assessed throughout the', 'study. Apalutamide will be dosed at the current recommended Phase II dose of 240 mg daily', 'by mouth.', '10.1.', 'Study Design and Sample Size', 'We will use a Simon minimax 2-stage design, which will allow early stopping for', 'futility after the first stage if the response rate is low. We expect that in the absence of', 'treatment, approximately 20% of patients will have a negative repeat biopsy. 53 We also', 'assume that >40% of treated patients must achieve a negative repeat biopsy to warrant', 'further investigation of this treatment approach in active surveillance patients. Thus,', 'our null and alternative hypotheses are Ho: p<20% VS. H1: p>40%. The minimax 2-stage', 'design for these parameters requires a first stage enrolling 18 patients. If 4 of 18 have', 'a negative repeat biopsy the trial is stopped and Ho cannot be rejected. If >4 of 18', 'patients respond, enrollment in that cohort continues until 33 patients have completed', 'the trial, and the response rate is calculated for all 33 patients. If <10 of 33 patients', 'have a negative repeat biopsy the null hypothesis cannot be rejected. This design will', 'provide 80% power to detect a response rate of 40% (one-sided a=0.05). This design', 'also provides a 72% probability of early stopping if Ho is true, affording protection', 'against treating more patients than necessary if the treatment is not effective.92', '10.2.', 'Data Analysis', 'The primary objective is to determine the negative repeat biopsy rate following', 'treatment with apalutamide in men enrolled in active surveillance. This rate will be', 'presented as the percent of subjects with a negative repeat biopsy, and will be', 'calculated as: (Number of patients with a negative biopsy following 90-days of', 'apalutamide) / (Total number of patients enrolled on the study) X 100. For details on the', '69', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}